Department of Respiratory Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
Dipartimento Universitario di Promozione della Salute, Materno Infantile, Medicina Interna e Specialistica di Eccellenza "G. D'Alessandro" (PROMISE) c/o Pneumologia, AOUP "Policlinico Paolo Giaccone", University of Palermo, Palermo, Italy.
Handb Exp Pharmacol. 2023;280:85-106. doi: 10.1007/164_2022_598.
Asthma is a complex, heterogeneous disease that necessitates a proper patient evaluation to decide the correct treatment and optimize disease control. The recent introduction of new target therapies for the most severe form of the disease has heralded a new era of treatment options, intending to treat and control specific molecular pathways in asthma pathophysiology. Precision medicine, using omics sciences, investigates biological and molecular mechanisms to find novel biomarkers that can be used to guide treatment selection and predict response. The identification of reliable biomarkers indicative of the pathological mechanisms in asthma is essential to unravel new potential treatment targets. In this chapter, we provide a general description of the currently available -omics techniques, focusing on their implications in asthma therapy.
哮喘是一种复杂的、异质的疾病，需要进行适当的患者评估，以确定正确的治疗方法并优化疾病控制。最近针对疾病最严重形式的新靶向治疗方法的出现，标志着治疗选择的新时代的到来，旨在治疗和控制哮喘病理生理学中的特定分子途径。精准医学利用组学科学研究生物和分子机制，以寻找新的生物标志物，用于指导治疗选择和预测反应。确定哮喘病理机制的可靠生物标志物对于揭示新的潜在治疗靶点至关重要。在本章中，我们提供了目前可用的组学技术的概述，重点介绍了它们在哮喘治疗中的意义。
